UCHL1 and breast cancer: By the same token, cancers that are sensitive to UCHL1 inhibition, but in which the phenotypic outcome or mechanism of action is postulated to be orthogonal to breast cancer, could also benefit from studies using IMP-1710 as a selective and potent probe.